Mesoblast LTD (MEOBF)
MEOBF is quoted over the counter, not listed on an exchange. Mesoblast LTD files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | MEOBF, quoted over the counter |
| SEC CIK | 0001345099 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | Melbourne, Victoria, Australia |
| Incorporated in | Australia |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-08-27 |
| Cash and burn | $102.9M cash; operating cash flow -$11.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 129,686,278 (2026-06-30); 127,996,719 a year earlier; 81,420,483 three years earlier. 3y figure adjusted for split (1-for-2 overall). | Cover page 2026-06-30 |
| Reverse splits, 3 years | 1; latest 1-for-2 on 2024-01-10 | Source 2024-01-10 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2025-12-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers, Melbourne, Australia | PCAOB Form AP 2026-09-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $19.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $120.3M | -$57.5M | -$43.8M | $102.9M | $119.2M | $120.3M | 20-F 2026-08-27 |
| FY 2025 2025-06-30 | $17.2M | -$102.1M | -$50.0M | $161.6M | $121.9M | $17.2M | 20-F 2025-08-29 |
| FY 2024 2024-06-30 | $5.9M | -$88.0M | -$48.5M | $63.0M | $114.3M | $5.9M | 20-F 2025-08-29 |
| FY 2023 2023-06-30 | $7.5M | -$81.9M | -$63.3M | $71.3M | $108.8M | $7.5M | 20-F 2025-08-29 |
| FY 2022 2022-06-30 | $10.2M | -$91.3M | -$65.8M | $60.4M | $101.7M | $10.2M | 20-F 2024-08-29 |
| FY 2021 2021-06-30 | $7.4M | -$98.8M | -$100.7M | $136.9M | $147.4M | $7.4M | 20-F 2023-08-31 |
| FY 2020 2020-06-30 | $32.2M | -$77.9M | -$50.4M | $129.3M | $89.5M | $32.2M | 20-F 2022-08-31 |
| FY 2019 2019-06-30 | $16.7M | -$89.8M | -$57.8M | $50.4M | $81.3M | $16.7M | 20-F 2021-08-31 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-01-14 |
| Latest annual report | 20-F | 2026-08-27 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 600 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier